Trademark: 79243223
Word
LIPTIDE
Status
Registered
Status Code
700
Status Date
Tuesday, April 28, 2020
Serial Number
79243223
Registration Number
6039104
Registration Date
Tuesday, April 28, 2020
Mark Type
4000
Filing Date
Monday, July 30, 2018
Published for Opposition
Tuesday, February 11, 2020

Trademark Owner History
Nanogenics Limited - Original Registrant

Classifications
5 Pharmaceutical preparations and substances for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; chemicals for pharmaceutical use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; pharmaceuticals and pharmaceutical preparations being nanoparticles for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; pharmaceuticals and pharmaceutical preparations containing siRNA for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; pharmaceuticals and pharmaceutical preparations containing RNA for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; pharmaceuticals and pharmaceutical preparations containing shRNA for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; pharmaceuticals and pharmaceutical preparations containing mRNA for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; pharmaceuticals and pharmaceutical preparations containing DNA for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; drug delivery agents being made from lipids, liposomes or peptides in the form of nanoparticles that facilitate the delivery of a wide variety of pharmaceuticals; pharmaceuticals and pharmaceutical preparations containing lipids, liposomes or peptides for treatments in the form of gene therapy used in the treatment of cancer; drug delivery agents in the form of nanoparticles that facilitate the delivery of a wide variety of pharmaceuticals; drug delivery agents that facilitate the delivery of pharmaceuticals and pharmaceutical preparations in the form of nanoparticles; intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations; pharmaceutical and drug delivery agents for use in relation to the delivery of siRNA, shRNA, mRNA, RNA, DNA or other genetic material in the form of nanoparticles; preparations for detecting genetic predispositions for medical purposes; pharmaceuticals and pharmaceutical preparations for use in gene therapy in the form of nanoparticles used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; drug delivery agents for use in gene therapy in the form of nanoparticles that facilitate the delivery of a wide variety of pharmaceuticals; drug delivery agents being nanoparticles in the form of an artificial virus that facilitate the delivery of a wide variety of pharmaceuticals; pharmaceutical and natural remedies for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; medical preparations for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; biochemical preparation for medical purposes for treatments in the form of gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; biological preparations for medical purposes for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; reagents for medical use; reagents for use in medical genetic testing; anti-cancer preparations; anti-cancer drugs; compounds for treating cancer; biopharmaceuticals for the treatment of cancer; anti-cancer preparations of chemical origin; anti-cancer preparations of plant origin; anti-cancer preparations of microbial origin; pharmaceutical preparations for the treatment of cancer; pharmaceutical products for the treatment of cancer; biological preparations for the treatment of cancer; anti-cancer preparations from hormones and antagonists; pharmaceutical preparations and substances for the prevention of cancer; chemotherapeutics for use in the treatment of cancer; pharmaceutical preparations for use in chemotherapy for the treatment of cancer; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for the treatment and prevention of tumours

Trademark Events
Sep 26, 2020
Final Decision Transaction Processed By Ib
Sep 8, 2020
Final Disposition Notice Sent To Ib
Sep 5, 2020
Final Disposition Processed
Jul 28, 2020
Final Disposition Notice Created, To Be Sent To Ib
Apr 28, 2020
Registered-Principal Register
Apr 3, 2020
Notification Of Possible Opposition - Processed By Ib
Mar 18, 2020
Notification Of Possible Opposition Sent To Ib
Mar 18, 2020
Notification Of Possible Opposition Created, To Be Sent To Ib
Feb 11, 2020
Official Gazette Publication Confirmation E-Mailed
Feb 11, 2020
Published For Opposition
Feb 7, 2020
Notification Processed By Ib
Jan 22, 2020
Notification Of Possible Opposition Sent To Ib
Jan 22, 2020
Notice Of Start Of Opposition Period Created, To Be Sent To Ib
Jan 22, 2020
Notification Of Notice Of Publication E-Mailed
Jan 3, 2020
Approved For Pub - Principal Register
Dec 26, 2019
Teas/Email Correspondence Entered
Dec 26, 2019
Correspondence Received In Law Office
Dec 26, 2019
Teas Request For Reconsideration Received
Jun 28, 2019
Notification Of Final Refusal Emailed
Jun 28, 2019
Final Refusal E-Mailed
Jun 28, 2019
Final Refusal Written
Jun 7, 2019
Teas/Email Correspondence Entered
Jun 7, 2019
Correspondence Received In Law Office
Jun 3, 2019
Assigned To Lie
May 29, 2019
Teas Response To Office Action Received
Apr 11, 2019
New Representative At Ib Received
Dec 28, 2018
Refusal Processed By Ib
Dec 7, 2018
Non-Final Action Mailed - Refusal Sent To Ib
Dec 7, 2018
Refusal Processed By Mpu
Nov 24, 2018
Non-Final Action (Ib Refusal) Prepared For Review
Nov 23, 2018
Non-Final Action Written
Nov 15, 2018
Assigned To Examiner
Oct 23, 2018
Application Filing Receipt Mailed
Oct 19, 2018
New Application Office Supplied Data Entered In Tram
Oct 18, 2018
Sn Assigned For Sect 66a Appl From Ib

Trademark Alertz updated from USPTO on 2030-01-24